← Leaderboards
Mary L. Disis
University Of Washington
$210,448,010
Attributed
$213,136,172
Total exposure
49
Grants
45
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $29.1M · FY2005–23$50M$37.5M$25M$12.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$274,399,459 · 53
By mechanism
UL1$219,199,639 · 26
KL2$21,822,366 · 2
R01$11,860,678 · 6
U54$5,817,645 · 2
TL1$4,804,462 · 2
U19$4,038,890 · 1
Top collaborators
- Leanna J Standish6 shared
- Peter A Cohen5 shared
- Lupe G Salazar5 shared
- Ronald Swensen5 shared
Most similar at University Of Washington
Same institution · by research overlap
- Connie L Celum$55,222,861
- Jairam Rao Lingappa$17,018,282
- Jared Baeten$17,463,749
- Lisa E Manhart$10,223,947
- William H George$6,588,489
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchBaseTranslational Health ScienceInstitutesResourcesTranslational ResearchInstitutionCollaborationsResearch PersonnelProgramsStagingWashingtonUniversitiesInnovationCommunitiesFundingMemberFred Hutchinson Cancer Research CenterTrainingResearch InfrastructureTumorCancer PatientImmune ResponseClinical Trials
Grant awards (154)
Institute of Translational Health Sciences$10,514,446
UL1 · FY2023 · TR · contact PI
Institute of Translational Health Sciences$168,112
UL1 · FY2023 · TR · contact PI
Institute of Translational Health Sciences$153,162
UL1 · FY2023 · TR · contact PI
Institute of Translational Health Sciences$10,489,065
UL1 · FY2022 · TR · contact PI
Developing Community-Responsive mHealth and AI/ML: Understanding Perspectives of Hispanic Community Members in Washington State$304,164
UL1 · FY2022 · TR · contact PI
Institute of Translational Health Sciences$9,519,990
UL1 · FY2021 · TR · contact PI
Institute of Translational Health Sciences$9,377,356
UL1 · FY2020 · TR · contact PI
Institute of Translational Health Sciences$95,093
UL1 · FY2020 · TR · contact PI
Institute of Translational Health Sciences$9,374,914
UL1 · FY2019 · TR · contact PI
Institute of Translational Health Sciences$9,517,178
UL1 · FY2018 · TR · contact PI
Transform Dissemination and Implementation Science in CTSA Programs$281,259
UL1 · FY2018 · TR · contact PI
Institute of Translational Health Sciences$9,405,183
UL1 · FY2017 · TR · contact PI
Institute of Translational Health Sciences$9,821,490
UL1 · FY2016 · TR · contact PI
Institute of Translational Health Sciences$2,512,119
KL2 · FY2016 · TR · contact PI
Institute of Translational Health Sciences$583,123
TL1 · FY2016 · TR · contact PI
Institute of Translational Health Sciences$101,459
UL1 · FY2016 · TR · contact PI
Institute of Translational Health Sciences$9,820,430
UL1 · FY2015 · TR · contact PI
Institute of Translational Health Sciences$2,512,119
KL2 · FY2015 · TR · contact PI
Institute of Translational Health Sciences$1
TL1 · FY2015 · TR · contact PI
Institute of Translational Health Sciences$9,820,822
UL1 · FY2014 · TR · contact PI
Institute of Translational Health Sciences$2,512,119
KL2 · FY2014 · TR · contact PI
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy$570,144
R01 · FY2014 · CA · contact PI
Institute of Translational Health Sciences$451,157
TL1 · FY2014 · TR · contact PI
Institute of Translational Health Sciences$112,590
UL1 · FY2014 · TR · contact PI
Institute of Translational Health Sciences$9,035,117
UL1 · FY2013 · TR · contact PI
Institute of Translational Health Sciences$2,512,119
KL2 · FY2013 · TR · contact PI
Institute of Translational Health Sciences$927,632
UL1 · FY2013 · TR · contact PI
Immune diagnostics and vaccine targets: breast cancer antigens from mice to women$699,023
U01 · FY2013 · CA · contact PI
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy$554,758
R01 · FY2013 · CA · contact PI
Institute of Translational Health Sciences$545,630
TL1 · FY2013 · TR · contact PI
Vaccinating against IGFBP-2 to prevent ovarian cancer relapse$321,413
P50 · FY2013 · CA · contact PI
Bastyr/UW Oncomycology Translational Research Center$300,784
U19 · FY2013 · AT
Institute of Translational Health Sciences$9,802,566
UL1 · FY2012 · TR · contact PI
Institute of Translational Health Sciences$2,512,119
KL2 · FY2012 · TR · contact PI
Bastyr/UW Oncomycology Translational Research Center$1,207,565
U19 · FY2012 · AT
Immune diagnostics and vaccine targets: breast cancer antigens from mice to women$753,681
U01 · FY2012 · CA · contact PI
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy$611,011
R01 · FY2012 · CA · contact PI
Institute of Translational Health Sciences$545,630
TL1 · FY2012 · TR · contact PI
Vaccinating against IGFBP-2 to prevent ovarian cancer relapse$347,224
P50 · FY2012 · CA · contact PI
Bastyr/UW Oncomycology Translational Research Center$142,000
U19 · FY2012 · AT
Institute for Translational Health Science (UL1)$9,832,606
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$5,759,575
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$2,879,788
UL1 · FY2011 · RR · contact PI
Bastyr/UW Oncomycology Translational Research Center$1,106,200
U19 · FY2011 · AT
Immune diagnostics and vaccine targets: breast cancer antigens from mice to women$729,351
U01 · FY2011 · CA · contact PI
Institute for Translational Health Science (TL1)$541,302
TL1 · FY2011 · RR · contact PI
Adoptive T Cell Therapy for the Treatment of HER2 Overexpressing Cancers$530,353
R01 · FY2011 · CA · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$506,631
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$506,630
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC CLINICAL TRIALS$479,981
UL1 · FY2011 · RR · contact PI
Vaccinating against IGFBP-2 to prevent ovarian cancer relapse$437,712
P50 · FY2011 · CA · contact PI
Institute for Translational Health Science (UL1)$299,999
UL1 · FY2011 · RR · contact PI
Bastyr/UW Oncomycology Translational Research Center$134,898
U19 · FY2011 · AT
Institute for Translational Health Science (KL2)$1
KL2 · FY2011 · RR · contact PI
Institute for Translational Health Science (UL1)$9,926,823
UL1 · FY2010 · RR · contact PI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$5,856,826
UL1 · FY2010 · RR · contact PI
Institute for Translational Health Science (KL2)$2,491,921
KL2 · FY2010 · RR · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$1,389,755
UL1 · FY2010 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$1,290,487
UL1 · FY2010 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$1,290,487
UL1 · FY2010 · RR · contact PI
Bastyr/UW Oncomycology Translational Research Center$1,147,443
U19 · FY2010 · AT
Immune diagnostics and vaccine targets: breast cancer antigens from mice to women$771,321
U01 · FY2010 · CA · contact PI
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.$572,160
R01 · FY2010 · CA · contact PI
Adoptive T Cell Therapy for the Treatment of HER2 Overexpressing Cancers$564,953
R01 · FY2010 · CA · contact PI
Institute for Translational Health Science (TL1)$538,536
TL1 · FY2010 · RR · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC CLINICAL TRIALS$527,980
UL1 · FY2010 · RR · contact PI
Institute for Translational Health Science (UL1)$483,614
UL1 · FY2010 · RR · contact PI
Institute for Translational Health Science (UL1)$428,712
UL1 · FY2010 · RR · contact PI
Mechanisms of immunomodulatory and anti-tumor actions of Polysaccharide Krestin$379,491
R01 · FY2010 · AT · contact PI
Vaccinating against IGFBP-2 to prevent ovarian cancer relapse$369,911
P50 · FY2010 · CA · contact PI
Institute for Translational Health Science (UL1)$9,921,720
UL1 · FY2009 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$2,941,294
UL1 · FY2009 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$2,941,294
UL1 · FY2009 · RR · contact PI
Institute for Translational Health Science (KL2)$2,444,713
KL2 · FY2009 · RR · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$1,897,033
UL1 · FY2009 · RR · contact PI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$1,698,499
UL1 · FY2009 · RR · contact PI
Immune diagnostics and vaccine targets: breast cancer antigens from mice to women$787,633
U01 · FY2009 · CA · contact PI
Mechanisms of immunomodulatory and anti-tumor actions of Polysaccharide Krestin$664,000
R01 · FY2009 · AT · contact PI
Institute for Translational Health Science (UL1)$596,069
UL1 · FY2009 · RR · contact PI
Institute for Translational Health Science (UL1)$590,641
UL1 · FY2009 · RR · contact PI
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.$582,940
R01 · FY2009 · CA · contact PI
Adoptive T Cell Therapy for the Treatment of HER2 Overexpressing Cancers$569,354
R01 · FY2009 · CA · contact PI
Institute for Translational Health Science (TL1)$535,231
TL1 · FY2009 · RR · contact PI
Institute for Translational Health Science (UL1)$499,930
UL1 · FY2009 · RR · contact PI
INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE (UL1): BPCA$499,930
UL1 · FY2009 · RR · contact PI
INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE$443,600
UL1 · FY2009 · RR · contact PI
Vaccinating against IGFBP-2 to prevent ovarian cancer relapse$387,723
P50 · FY2009 · CA · contact PI
Mechanisms of immunomodulatory and anti-tumor actions of Polysaccharide Krestin$385,472
R01 · FY2009 · AT · contact PI
Institute for Translational Health Science (UL1)$382,099
UL1 · FY2009 · RR · contact PI
Institute for Translational Health Science (UL1)$296,314
UL1 · FY2009 · RR · contact PI
Institute for Translational Health Science (UL1)$9,919,954
UL1 · FY2008 · RR · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$3,288,984
UL1 · FY2008 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$3,116,946
UL1 · FY2008 · RR · contact PI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$2,944,907
UL1 · FY2008 · RR · contact PI
Institute for Translational Health Science (KL2)$2,461,009
KL2 · FY2008 · RR · contact PI
INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE$769,117
UL1 · FY2008 · RR · contact PI
Adoptive T Cell Therapy for the Treatment of HER2 Overexpressing Cancers$571,699
R01 · FY2008 · CA · contact PI
Institute for Translational Health Science (TL1)$531,926
TL1 · FY2008 · RR · contact PI
Mechanisms of immunomodulatory and anti-tumor actions of Polysaccharide Krestin$386,048
R01 · FY2008 · AT · contact PI
Institute for Translational Health Science (UL1)$200,000
UL1 · FY2008 · RR · contact PI
Institute for Translational Health Science (UL1)$8,074,693
UL1 · FY2007 · RR · contact PI
INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE PEDIATRIC RESEARCH$3,633,612
UL1 · FY2007 · RR · contact PI
INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE FOR CLINICAL TRIALS$3,229,877
UL1 · FY2007 · RR · contact PI
Institute for Translational Health Science$1,864,127
KL2 · FY2007 · RR · contact PI
INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE FOR AIDS RESEARCH$1,211,204
UL1 · FY2007 · RR · contact PI
Institute for Translational Health Science (TL1)$531,926
TL1 · FY2007 · RR · contact PI
Mechanisms of immunomodulatory and anti-tumor actions of Polysaccharide Krestin$410,922
R01 · FY2007 · AT · contact PI
Multi-Antigen Vaccines for Breast Cancer$323,425
R01 · FY2007 · CA · contact PI
Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine$319,238
R01 · FY2007 · CA · contact PI
SAFETY AND IMMUNOGENICITY STUDY OF DNA PLASMID BASED VACCINE FOR TUMORS$7,535
M01 · FY2007 · RR · contact PI
PHASE I-II STUDY OF COMBINATION IMMUNOTHERAPY FOR HER-2/NEU CYTOTOXIC T CELLS$2,053
M01 · FY2007 · RR · contact PI
PHASE II STUDY OF A HER-2/NEU INTRACELLULAR DOMAIN (ICD) PEPTIDE-BASED VACCINE$609
M01 · FY2007 · RR · contact PI
NOVEL METHOLD OF IMMUNOLOGIC MONITORING FOR ASSESSING CANCER IMMUNOTHERAPIES$75
M01 · FY2007 · RR · contact PI
Immunologic Correlates of Immunization for Cancer$431,677
U54 · FY2006 · CA · contact PI
Multi-Antigen Vaccines for Breast Cancer$333,085
R01 · FY2006 · CA · contact PI
Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine$320,087
R01 · FY2006 · CA · contact PI
Planning Grant for Institutional Clinical and Translational Science Award$250,330
P20 · FY2006 · RR · contact PI
PLANNING GRANT FOR INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARD$250,330
P20 · FY2006 · RR · contact PI
SAFETY AND IMMUNOGENICITY STUDY OF DNA PLASMID BASED VACCINE FOR TUMORS$47,964
M01 · FY2006 · RR · contact PI
PHASE I-II STUDY OF COMBINATION IMMUNOTHERAPY FOR HER-2/NEU CYTOTOXIC T CELLS$40,522
M01 · FY2006 · RR · contact PI
A FEASIBILITY STUDY OF EX VIVO EXPANSION AND INFUSION OF HER2 T CELLS$14,266
M01 · FY2006 · RR · contact PI
NOVEL METHODS OF IMMUNOLOGIC MONITORING FOR ASSESSING CANCER IMMUNOTHERAPIES$4,962
M01 · FY2006 · RR · contact PI
Immunologic Correlates of Immunization for Cancer$832,603
U54 · FY2005 · CA
Multi-Antigen Vaccines for Breast Cancer$341,100
R01 · FY2005 · CA
PHASE I-II STUDY OF COMBINATION IMMUNOTHERAPY FOR HER-2/NEU CYTOTOXIC T CELLS$36,370
M01 · FY2005 · RR
SAFETY AND IMMUNOGENICITY STUDY OF DNA PLASMID BASED VACCINE FOR TUMORS$15,689
M01 · FY2005 · RR
NOVEL METHODS OF IMMUNOLOGIC MONITORING FOR ASSESSING CANCER IMMUNOTHERAPIES$1,427
M01 · FY2005 · RR
Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine$1
R01 · FY2005 · CA
Immunologic Correlates of Immunization for Cancer$1,105,804
U54 · FY2004 · CA
Multi-Antigen Vaccines for Breast Cancer$341,100
R01 · FY2004 · CA
Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine$319,158
R01 · FY2004 · CA
HER2 VACCINATION FOR THE TREATMENT OF CANCER$317,735
R01 · FY2004 · CA
MIDCAREER INVESTIGATOR AWARD IN PATIENT ORIENTED RESEARC$119,903
K24 · FY2004 · CA
Novel methods of immunologic monitoring for assessing cancer immunotherapies$3,470
M01 · FY2004 · RR
Phase I-II study of combination immunotherapy for HER-2/neu cytotoxic T cells$433
M01 · FY2004 · RR
Immunologic Correlates of Immunization for Cancer$1,240,135
U54 · FY2003 · CA
Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine$367,441
R01 · FY2003 · CA
Multi-Antigen Vaccines for Breast Cancer$341,100
R01 · FY2003 · CA
HER2 VACCINATION FOR THE TREATMENT OF CANCER$309,226
R01 · FY2003 · CA
MIDCAREER INVESTIGATOR AWARD IN PATIENT ORIENTED RESEARC$117,587
K24 · FY2003 · CA
Immunologic Correlates of Immunization for Cancer$1,221,861
U54 · FY2002 · CA
HER2 VACCINATION FOR THE TREATMENT OF CANCER$300,218
R01 · FY2002 · CA
ANTIBODIES AS A MARKER OF EFFECTIVE IMMUNIZATION$296,752
U54 · FY2002 · CA
MIDCAREER INVESTIGATOR AWARD IN PATIENT ORIENTED RESEARC$114,295
K24 · FY2002 · CA
H2N PEPTIDE VACCINE IN PTS WITH H2N EXPRESSING CANCER$0
M01 · FY2002 · RR
Immunologic Correlates of Immunization for Cancer$688,813
U54 · FY2001 · CA
HER2 VACCINATION FOR THE TREATMENT OF CANCER$291,475
R01 · FY2001 · CA
MIDCAREER INVESTIGATOR AWARD IN PATIENT ORIENTED RESEARC$111,103
K24 · FY2001 · CA
ANTIBODIES AS A MARKER OF EFFECTIVE IMMUNIZATION$0
U54 · FY2001 · CA
H2N PEPTIDE VACCINE IN PTS WITH H2N EXPRESSING CANCER$0
M01 · FY2001 · RR
HER2 VACCINATION FOR THE TREATMENT OF CANCER$282,984
R01 · FY2000 · CA
MIDCAREER INVESTIGATOR AWARD IN PATIENT ORIENTED RESEARC$108,000
K24 · FY2000 · CA
STUDY OF A H2N PEPTIDE VACCINE IN PATIENTS WITH ADVANCED H2N EXPRESSING CANCERS$3,864
M01 · FY2000 · RR
H2N PEPTIDE VACCINE IN PTS WITH H2N EXPRESSING CANCER$0
M01 · FY2000 · RR